Bone and Joint Infections from Microbiology to Diagnostics and Treatment, 2e
In the newly revised Second Edition of Bone and Joint Infections: From Microbiology to Diagnostics and Treatment, accomplished researcher and author Werner Zimmerli delivers a comprehensive overview of the most recent developments in the subject of bone and joint infection. Covering much of the new information appearing over the last five years, the book includes four new chapters presenting the diagnostic approach in bone and joint infections, discussing the identification of pathogens by non-culture techniques, management of multi-resistant bacteria in bone and joint infections by bacteriophages, and unusual microorganisms in periprosthetic joint infections.
Many of the chapters are also updated to include new information on topics like eubacterial PCR, multiplex PCR, and the shotgun metagenomics approach. These subjects are of increased applicability and interest to increase the fraction of cases with identified pathogens. The book also helps clinicians to understand MRI-based images and rapidly interpret and plan for comprehensive therapy.
Readers will also benefit from the inclusion of:
- A thorough introduction to the pharmacokinetics and pharmacodynamics of antibiotics in bone and preclinical models of infection in bone and joint surgery
- An exploration of native joint arthritis in children and adults, as well as an overview of septic arthritis of axial joints
- A practical discussion of the general aspects of periprosthetic joint infection, as well as specific aspects of periprosthetic joint infection after total hip and knee, shoulder, elbow, and ankle arthroplasty
- A concise treatment of osteomyelitis in children and adults
Perfect for infectious disease specialists, microbiologists, orthopedic and trauma surgeons, and internists, Bone and Joint Infections: From Microbiology to Diagnostics and Treatment will also earn a place in the libraries of professionals working in the implant industry and pharmaceuticals, as well as clinical pharmacologists and rheumatologists.
|Published:||July 7, 2021|